Thomas Matthew, Hollingsworth Andrew, Mofidi Reza
Department of Vascular Surgery, Freeman Hospital, Newcastle-upon-Tyne, UK.
Department of Vascular Surgery, James Cook University Hospital, Middlesbrough, UK.
Ann Vasc Surg. 2019 Jul;58:363-370. doi: 10.1016/j.avsg.2018.12.067. Epub 2019 Feb 13.
Deep vein thrombosis (DVT) is associated with significant complications, including the development of post-thrombotic syndrome (PTS). Traditional management is with oral anticoagulation, but the endovascular techniques of catheter-directed thrombolysis (CDT), pharmacomechanical thrombolysis, and venous stenting are now increasingly used. This study aims to review the evidence for these endovascular techniques in the management of acute lower limb DVT, and their role in the reduction of complications such as PTS.
A systematic review and meta-analysis was carried out, with studies that compared CDT, pharmacomechanical thrombolysis, and/or venous stenting with oral anticoagulation included. Primary outcome measure was the incidence of PTS; secondary outcome measures were the incidence of recurrent venous thromboembolism (VTE) and bleeding complications. Treatment effects were calculated as risk ratios (RR) with their 95% confidence interval (CI).
Five studies met the final inclusion criteria. CDT reduced the incidence of PTS (RR 0.56, 95% CI 0.43-0.73), whereas pharmacomechanical thrombolysis had only a minor effect on the incidence of PTS that did not achieve statistical significance (RR 0.87, 95% CI 0.75-1.01). Recurrent VTE following CDT was reduced compared to oral anticoagulation (RR 0.62, 95% CI 0.34-1.13), while bleeding complications were more likely following CDT (RR 5.11, 95% CI 2.16-12.08).
CDT decreases the incidence of PTS when treating iliofemoral DVT, but pharmacomechanical thrombolysis does not. CDT also reduces the incidence of recurrent VTE, but leads to more bleeding complications when compared to oral anticoagulation. Further randomized controlled trials are needed to determine the role of endovascular management of DVT occurring below the iliofemoral level, and the role of venous stenting.
深静脉血栓形成(DVT)与包括血栓后综合征(PTS)在内的严重并发症相关。传统治疗方法是口服抗凝药,但导管定向溶栓(CDT)、药物机械性溶栓和静脉支架置入等血管内技术目前的应用越来越广泛。本研究旨在综述这些血管内技术在急性下肢DVT治疗中的证据,以及它们在减少诸如PTS等并发症方面的作用。
进行了一项系统评价和荟萃分析,纳入了比较CDT、药物机械性溶栓和/或静脉支架置入与口服抗凝药的研究。主要结局指标是PTS的发生率;次要结局指标是复发性静脉血栓栓塞(VTE)和出血并发症的发生率。治疗效果以风险比(RR)及其95%置信区间(CI)计算。
五项研究符合最终纳入标准。CDT降低了PTS的发生率(RR 0.56,95%CI 0.43 - 0.73),而药物机械性溶栓对PTS发生率的影响较小,未达到统计学意义(RR 0.87,95%CI 0.75 - 1.01)。与口服抗凝药相比,CDT后复发性VTE有所减少(RR 0.62,95%CI 0.34 - 1.13),而CDT后出血并发症更有可能发生(RR 5.11,95%CI 2.16 - 12.08)。
治疗髂股静脉DVT时,CDT可降低PTS的发生率,但药物机械性溶栓不能。CDT还降低了复发性VTE的发生率,但与口服抗凝药相比会导致更多出血并发症。需要进一步的随机对照试验来确定血管内治疗在髂股静脉水平以下发生的DVT中的作用,以及静脉支架置入的作用。